Data on cannabis adverse reactions: 2024 annual report (English, PDF)

View metadata and access the original English PDF file: Data on cannabis adverse reactions: 2024 annual report.

Format

PDF

Access

file-only

Size

911,560 bytes

Publisher-reported update

2025-10-21

Adverse reaction data with respect to cannabis products are one of several important indicators of the impact of legalization and regulation of cannabis on the health and safety of Canadian consumers and the risks associated with the real-world use of these products. Health Canada conducts near-time monitoring, detection, and assessment of cases of adverse reactions involving cannabis products as part of the Vigilance Framework for Cannabis Products in Canada. Health Canada also monitors cases involving cannabis as a substance for broader issues of public health importance such as vaping-associated lung illness (https://www.canada.ca/en/public-health/services/diseases/vaping-pulmonary-illness.html), cases involving pediatric populations from studies like the study on serious and life-threatening events associated with non-medical (recreational) cannabis use in Canadian children and youth(https://cpsp.cps.ca/surveillance/study-etude/serious-and-life-threatening-events-associated-with-non-medical-recreational-cannabis-use-in-canadian-children-and-youth), and other potential emerging safety issues (for example, potential drug interactions, like cannabis and…

Access original file